Results of 202 phase II and III clinical trials conducted between 1989 and 2019 on 23, 296 cancer patients has revealed "greater severity of both symptomatic adverse events and haematology adverse events in women across multiple treatment modalities." Researchers at the SWOG Cancer Research Network determined that of the 23, 296 patients studies (8,838/37.9% women and 14,458/62.1% men) female patients "had a 34% increased risk of adverse events [across various cancer therapies administered] compared to men."
To learn more about this study, click here.
Source mentioned: Unger JM, Vaidya R, Albain KS, et al. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. JCO; Published online 4 February 2022. DOI: 10.1200/JCO.21.02377
No comments:
Post a Comment